BioSpace News Archive

Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that medical linear accelerators are excluded from the additional tariffs China imposed on US products that began on August 23, 2018.

The Consumer Advocates for Smoke-free Alternatives Association is a non-profit 501(c)(4) organization with an all-volunteer board and a grassroots membership of more than 250,000 active members from all walks of life.

Gracell Biotechnologies Co., Ltd. (“Gracell”), a clinical-stage immune cell therapy company, today announced a positive continued clinical readout of a multi-center pilot study designed to evaluate the safety and efficacy of Gracell’s first-in-class FasT CAR-19 (GC007F) investigational cell gene therapy.

Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), the market leader in Transcranial Magnetic Stimulation (“TMS”) in the United States, announced today that it has, through its wholly-owned subsidiary TMS NeuroHealth Centers Inc., entered into a purchase agreement pursuant to which Greenbrook will acquire Achieve TMS Centers, LLC and Achieve TMS Alaska, LLC (collectively, “Achieve TMS”).

A new traveling exhibition “For the Greatest Benefit to Humankind” will open on Sept. 11, in Mohali, India.

The initial pricing of the term loan is LIBOR plus 2.50%. SunTrust Robinson Humphrey, Inc served as left lead arranger and SunTrust Bank is acting as administrative agent for the facility.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, commends the U.S. Environmental Protection Agency (EPA) for yesterday’s pledge “to aggressively reduce animal testing” with the goal of “completely eliminating them by 2035.

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced their participation at the World Bispecific Summit occurring September 17-19, 2019 in Waltham, MA

Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, announced today its financial and operational results for the fourth quarter and fiscal year ended June 30, 2019.

Mr. Michael Bonney, Dr. Julia A. Haller and Ms. Phyllis Yale to Join BMS Board as Independent Directors